ストックスクリーナーアプリを入手
5.81
4.75%
-0.29
アフターアワーズ：
5.86
0.05
+0.86%
前日終値:
$6.10
開ける：
$6.1
24時間の取引高:
479.43K
Relative Volume:
0.58
時価総額：
$502.32M
収益：
$46.02M
当期純損益:
$-70.80M
株価収益率:
-3.1923
EPS:
-1.82
ネットキャッシュフロー:
$-1.61M
1週間 パフォーマンス:
-20.41%
1か月 パフォーマンス:
+27.13%
6か月 パフォーマンス:
-50.04%
1年 パフォーマンス:
-54.14%
1日の値動き範囲:
$5.75
$6.23
1週間の範囲:
$5.75
$7.2458
52週間の値動き範囲:
$3.91
$13.98
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
名前
Eyepoint Pharmaceuticals Inc
セクター
電話
617-926-5000
住所
480 PLEASANT STREET, WATERTOWN, MA
EYPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
5.81 | 502.32M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-07 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-28 | 開始されました | Jefferies | Buy |
| 2024-01-22 | 開始されました | JP Morgan | Overweight |
| 2023-11-02 | 開始されました | Mizuho | Buy |
| 2023-04-21 | 開始されました | Robert W. Baird | Outperform |
| 2022-07-07 | 開始されました | Chardan Capital Markets | Buy |
| 2021-03-01 | 開始されました | Cowen | Outperform |
| 2021-01-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-04-06 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 再開されました | Laidlaw | Buy |
| 2019-09-12 | 開始されました | Guggenheim | Buy |
すべてを表示
Eyepoint Pharmaceuticals Inc (EYPT) 最新ニュース
Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum - MSN
EyePoint Pharmaceuticals (EYPT): Analyst Maintains Buy Rating, Lowers Price Target | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2025 Earnings Call Transcript - Insider Monkey
EyePoint Pharma’s Promising Q1 2025 Financial Results - TipRanks
EyePoint Pharmaceuticals: Q1 Earnings Snapshot - Midland Daily News
EyePoint Pharmaceuticals (EYPT) Reports Growth Amidst Trial Developments - GuruFocus
Transcript : EyePoint Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Earnings call transcript: EyePoint Pharmaceuticals Q1 2025: Revenue Surges - Investing.com
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
EyePoint (EYPT) Sees Strong Q1 Revenue Growth and Advances in DURAVYU Trials | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals Inc Surpasses Revenue Estimates with $24.5 Million in Q1 2025, EPS of ($0.65) Slightly Beats Expectations - GuruFocus
EyePoint Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments - EyePoint Pharmaceuticals
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 - EyePoint Pharmaceuticals
A Peek at EyePoint Pharmaceuticals's Future Earnings - Nasdaq
EyePoint Pharmaceuticals to Host Conference Call for Q1 2025 Financial Results on May 7 - Nasdaq
EyePoint Pharmaceuticals Q1 2025 Earnings and Corporate Updates: Join Live Call May 7 - Stock Titan
Pars Planitis Market Set to Grow Substantially Through 2032, - openPR.com
EyePoint (EYPT) Offers Stock Options as Inducement for New Hires | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EYPT Stock News - GuruFocus
Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Expands Team with Strategic Stock Options Package Worth $370K - Stock Titan
How the (EYPT) price action is used to our Advantage - news.stocktradersdaily.com
Nano Silicon Drug Delivery Platform Market to Witness Massive - openPR.com
Ex-Dividend Date Nearing for These 10 Stocks – Week of April 7, 2025 - The Globe and Mail
EyePoint Pharmaceuticals' US$84m Market Cap Fall Books Insider Losses - simplywall.st
EyePoint Pharmaceuticals at RBC Conference: Insights on Duravu’s Promise By Investing.com - Investing.com Canada
Compliance - EyePoint Pharmaceuticals
Working At Eyepoint - EyePoint Pharmaceuticals
Here's Why We're Watching EyePoint Pharmaceuticals' (NASDAQ:EYPT) Cash Burn Situation - Yahoo Finance
Long Term Trading Analysis for (EYPT) - news.stocktradersdaily.com
pSivida Corp Announces Transformative Acquisition Of Icon Bioscience - Reuters
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Analysts - Defense World
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - The Manila Times
EyePoint's CEO Takes Center Stage: Key Updates Coming at RBC Ophthalmology Conference - Stock Titan
What is Chardan Capital’s Estimate for EYPT FY2026 Earnings? - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Bought by Bank of New York Mellon Corp - Defense World
3 US Healthcare Stocks That Might Be Undervalued 2025 - Value The Markets
(EYPT) Investment Report - news.stocktradersdaily.com
Mizuho maintains EyePoint stock Outperform with $30 target By Investing.com - Investing.com Australia
Mizuho maintains EyePoint stock Outperform with $30 target - Investing.com India
EyePoint Expands Team with New Hires, Awards $6.52 Stock Options - Stock Titan
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga India
StockNews.com Upgrades EyePoint Pharmaceuticals (NASDAQ:EYPT) to “Sell” - Defense World
EyePoint Pharmaceuticals at Leerink’s Conference: DuraView’s Promising Potential By Investing.com - Investing.com Canada
Q1 EPS Estimate for EyePoint Pharmaceuticals Cut by Analyst - Defense World
Research Analysts Set Expectations for EYPT FY2025 Earnings - Defense World
EyePoint Pharmaceuticals Inc (EYPT) Reports Q3 2023 Financial Re - GuruFocus.com
Eyepoint Pharmaceuticals Inc (EYPT) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):